Vaccine carrier proteins (CRM197, Diphtheria toxoid, Tetanus toxoid)

Vaccine carrier proteins, including CRM197, diphtheria toxoid (DT), and tetanus toxoid (TT), are highly immunogenic proteins used in the development of conjugate vaccines to enhance the immune response against poorly immunogenic antigens, such as bacterial capsular polysaccharides. These polysaccharides are T-cell independent antigens that typically fail to induce a memory response or provide protection in infants. By covalently linking these antigens to a carrier protein, the resulting conjugate is internalized by B cells and processed into peptide fragments. These fragments, containing T-cell epitopes, are presented on MHC class II molecules to CD4+ T-helper cells, which then provide the necessary signals for B-cell affinity maturation, class switching, and the formation of long-lived memory B cells. CRM197 is a genetically detoxified mutant of diphtheria toxin (G52E), while DT and TT are chemically inactivated toxins. These carriers are critical components of widely used vaccines against pathogens such as Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis.

Other names

CRM197Diphtheria toxoidTetanus toxoidCross-reacting material 197DTTTCarrier protein epitopesVaccine carrier proteins

Carrier proteins provide T-cell epitopes that facilitate T-cell dependent immune responses to conjugated haptens. Upon B-cell receptor-mediated internalization of the conjugate, the protein component is proteolytically processed into peptides and presented on MHC class II molecules to CD4+ T-helper cells. This interaction stimulates B-cell proliferation, antibody class switching from IgM to IgG, and the generation of immunological memory.